Relevant bibliographies by topics / Seiwert / Journal articles
To see the other types of publications on this topic, follow the link: Seiwert.

Journal articles on the topic 'Seiwert'

Author: Grafiati
Published: 4 June 2021
Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 20 journal articles for your research on the topic 'Seiwert.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mettin, Martin. "Elvira Seiwert: Enthüllungen." Zeitschrift für philosophische Literatur 6, no. 1 (February 13, 2018): 20–28. http://dx.doi.org/10.21827/zfphl.6.1.35416.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hexham, Irving, and Karla Poewe. "Source Criticism and the Reconstruction of Reality A Reply to Brigitte Schoen and Hubert Seiwert." Nova Religio 6, no. 1 (October 1, 2002): 129–36. http://dx.doi.org/10.1525/nr.2002.6.1.129.

Full text
Abstract:
This paper responds to criticism of our earlier work on the German anticult debate by Ms. Schoen and Prof. Dr. Seiwert. In it we argue that Schoen misunderstood and misread our article as a result of her obsession with published texts. Both Schoen and Seiwert underestimate the importance of history in creating the ethos that shapes the German debate about new religions.
APA, Harvard, Vancouver, ISO, and other styles
3

Hake, Sabine. "Proletarian Modernism and the Politics of Emotion: On Franz Wilhelm Seiwert and John Heartfield." Modernism/modernity 27, no. 4 (2020): 735–67. http://dx.doi.org/10.1353/mod.2020.0061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Son, Min Young, Sung Eun Kim, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, and Kyoung won Jung. "Tu1319 – Predictive Factors of Lymph Node Metastasis in Early Gastric Cancer Patients with Seiwert Type Ii/Iii." Gastroenterology 156, no. 6 (May 2019): S—1025. http://dx.doi.org/10.1016/s0016-5085(19)39516-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tokunaga, Masanori, Eigo Akimoto, Reo Sato, Akio Kaito, and Takahiro Kinoshita. "Surgical outcomes of laparoscopic transhiatal lower mediastinal lymphadenectomy for seiwert type II adenocarcinoma of the esophagogastric junction." Journal of Clinical Oncology 37, no. 4_suppl (February 1, 2019): 155. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.155.

Full text
Abstract:
155 Background: Optimal surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction (AEG-II) has not yet been determined, presumably due to complex anatomical structures and the limited number of reports regarding this aspect. The transhiatal approach is preferred in East Asia in cases with 30 mm or less esophageal invasion, and laparoscopic surgery is increasingly performed. However, the feasibility of the laparoscopic transhiatal approach for AEG-II is still unclear, and thus was investigated in this study. Methods: A total of 51 consecutive patients who underwent total/proximal gastrectomy with lower mediastinal lymphadenectomy by laparoscopic transhiatal approach between January 2008 and May 2018 were included. Patients with greater than 30 mm esophageal invasion, and those who received preoperative chemotherapy, were excluded. Results: The male/female ratio was 38:13, and the median age (range) was 69 (37-81) years. Total gastrectomy and proximal gastrectomy were performed in 10 and 41 patients, respectively. All surgeries were performed by experienced surgical teams. Median operation time and intra-operative blood loss were 300 (141-511) minutes and 21 (0-267) g, respectively. Pathological tumor depth was T2 or deeper in 28 patients (55%), and nodal status was negative in 20 patients (39%). Clavien-Dindo grade IIIa or higher complications were observed in eight patients (16%), which included two anastomotic leakages and one pancreas fistula, and the mortality rate was 0%. The 5-year overall survival rate of all patients was 97% with a median observational period of 30 months. Conclusions: Laparoscopic transhiatal approach with lower mediastinal lymphadenectomy seems to be a technically feasible procedure, provided an experienced surgical team performs the surgeries. However, oncological safety for advanced disease needs to be confirmed, considering that the proportion of advanced stage cancer included in this study was limited.
APA, Harvard, Vancouver, ISO, and other styles
6

Corell, R. A., L. K. Read, G. R. Riley, J. K. Nellissery, T. E. Allen, M. L. Kable, M. D. Wachal, S. D. Seiwert, P. J. Myler, and K. D. Stuart. "Complexes from Trypanosoma brucei that exhibit deletion editing and other editing-associated properties." Molecular and Cellular Biology 16, no. 4 (April 1996): 1410–18. http://dx.doi.org/10.1128/mcb.16.4.1410.

Full text
Abstract:
Transcripts from many mitochondrial genes in kinetoplastids undergo RNA editing, a posttranscriptional process which inserts and deletes uridines. By assaying for deletion editing in vitro, we found that the editing activity from Trypanosoma brucei mitochondrial lysates (S.D. Seiwert and K.D. Stuart), Science 266:114-117,1994) sediments with a peak of approximately 20S. RNA helicase, terminal uridylyl transferase, RNA ligase, and adenylation activities, which may have a role in editing, cosediment in a broad distribution, with most of each activity at 35 to 40S. Most ATPase 6 (A6) guide RNA and unedited A6 mRNA sediments at 20 to 30S, with some sedimenting further into the gradient, while most edited A6 mRNA sediments at >35S. Several mitochondrial proteins which cross-link specifically with guide RNA upon UV treatment also sediment in glycerol gradients. Notably, a 65-kDa protein sediments primarily at approximately 20S, a 90-kDa protein sediments at 35 to 40S, and a 25-kDa protein is present at <10S. Most ribonucleoprotein complexes that form with gRNA in vitro sediment at 10 to 20S, except for one, which sediments at 30 to 45S. These results suggest that RNA editing takes place within a multicomponent complex. The potential functions of and relationships between the 20S and 35 to 40S complexes are discussed.
APA, Harvard, Vancouver, ISO, and other styles
7

Ownby, David. "Popular Religious Movements and Heterodox Sects in Chinese History. By Seiwert Hubert. Leiden and Boston: Brill, 2003. xvi, 548 pp. $118.00 (cloth)." Journal of Asian Studies 63, no. 4 (November 2004): 1110–13. http://dx.doi.org/10.1017/s0021911804002645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Choong, N. W., D. J. Haraf, E. E. Cohen, K. M. Stenson, E. A. Blair, A. Dekker, R. Williams, T. G. Karrison, and E. E. Vokes. "Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC)." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 6034. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6034.

Full text
Abstract:
6034 Background: Preclinical data supports inhibition of vascular endothelial growth factor (VEGF) to improve tumor radiosensitivity. Phase I data demonstates that BFHX was tolerable in HNC (Seiwert, pASCO2006). Here we present preliminary toxicity data from a randomized phase II trial in pts with PS 0–2, stage II-IV (T2–4 N0–1 M0) HNC. Methods: Pts were randomized (2:1) to receive either BFHX or FHX. Planned sample size is 72pts. Chemotherapy consists of 5- FU (600 mg/m2/day continuous infusion for 120 hrs), hydroxyurea (500 mg PO q12 hours for 11 doses) with or without bevacizumab (10 mg/kg IV on day 1), concurrently with twice daily RT on a week on-week off schedule. Results: 21pts (BFHX 14pt and FHX 7pt) have completed therapy and are evaluable for toxicity. Pt characteristics in the BFHX and FHX arms are: median age 61 vs. 55 yrs, males 78% vs. 85%, stage II-III 57% vs. 86% and IV 43% vs. 14%. All pts have PS 0–1. 20 pts are evaluable for toxicity. Two episodes of gr3 leukopenia and one episode of gr 3 neutropenia were observed in the BFHX arm; whereas no gr3 hematologic toxicities were seen in the FHX arm. Mucositis (Gr3 - BFHX 85% vs. FHX 86%) and dermatitis (Gr3 - 0% vs. 14%) were observed in every pt. Other common non- hematologic toxicities were pain (100% vs. 86%), fatigue (77% vs. 86%) and anorexia (62% vs. 51%). No hemorrhagic events were observed. In the BFHX arm, one episode of deep venous thrombosis and one non-neutropenic death from sepsis were observed. Pathologic complete response rates were 92% and 100% in the BFHX and FHX arms, respectively. Conclusions: Preliminary results support the tolerability of BFHX. Toxicity appears to be similar to FHX with an apparent increase in leukopenia consistent with prior reports. Bleeding complications were not increased with BFHX. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
9

Seiwert, Tanguy Y., Riyue Bao, Y.-H. Carol Tan, Rajesh Acharya, Ryan J. Brisson, Sara Kochanny, Saba Arshad, et al. "Correlation of constitutive PD-1 resistance in HNC with GM-CSF expression and presence of myeloid derived suppressor cells (MDSCs)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 6049. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.6049.

Full text
Abstract:
6049 Background: PD-1 checkpoint blockade is active in head and neck squamous cell carcinomas (HNC) with a response rate of ~18% and significant impact on survival. However, only a subset of patients benefits (Seiwert, Lancet Oncol). Biomarkers such as PD-L1 IHC and the Interferon-Gamma gene expression profile (INF-G GEP) identify inflamed tumors with a higher chance of response (~35-40%). However, it remains unclear why the majority of INF-G inflamed tumors still do not respond, or how to overcome constitutive resistance. Methods: 50 anti-PD-1 treated recurrent/metastatic HNC patients were included. Tumor RNA was analyzed using a 638-gene immune panel on the Nanostring nCounter. HPV status was assessed by HPV E6/E7 mRNA. T-cell inflamed phenotype was calculated using the 6-gene INF-G GEP (geometric mean) using both a low (6) and a high cutpoint. Differential gene expression was determined between inflamed-benefitting (IB) patients (defined as OS ≥ 250days), and inflamed-non-benefitting (INB) patients. Candidate biomarkers were evaluated in the entire cohort. Results: CD8 correlated highly with INF-G GEP (R = 0.80), suggesting T cell-driven inflammation. Comparing inflamed benefitting with inflamed non-benefitting tumors, the most differentially expressed gene was CSF-2, encoding GM-CSF, with 4-fold higher expression in inflamed non-benefitting (INB) tumors (with both cutpoints). In the overall anti-PD-1 treated cohort of 50 patients, CSF-2/GM-CSF correlated strongly with poor overall survival (P = 0.02), outperforming both HPV status, or PD-L1 expression in cox PH multivariate analysis. GM-CSF expression has been linked to myeloid derived suppressor cells (MDSC); MDSC marker CD34, as well as JAK2/IL10 were significantly elevated in inflamed non-benefitting (INB) tumors. There was no difference in M2 macrophage marker CD163 between the two groups. Conclusions: Constitutive resistance to PD-1 checkpoint blockade in inflamed HNC associates with expression of GM-CSF and Myeloid Derived Suppressor Cell (MDSC) markers. Strategies to deplete MDSCs, such as chemotherapy, should be considered in combination or sequentially with anti-PD-1.
APA, Harvard, Vancouver, ISO, and other styles
10

Mückl, Stefan. "Besier, Gerhard, Seiwert, Hubert (Hg.), Die Religionsfreiheit und das Staat-Kirche-Verhältnis in Europa und den USA, Berlin: LIT Verlag 2013, 165 S. (= Religion - Staat - Gesellschaft. Zeitschrift für Glaubensformen und Weltanschauungen 14/1)." Archiv für katholisches Kirchenrecht 182, no. 2 (June 24, 2013): 664–67. http://dx.doi.org/10.30965/2589045x-18202039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Machiels, Jean-Pascal H., Lisa F. Licitra, Robert I. Haddad, Makoto Tahara, Liz Svensson, Xiuyu Julie Cong, Eva Ehrnrooth, and Ezra E. W. Cohen. "LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS5598. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps5598.

Full text
Abstract:
TPS5598 Background: EGFR (ErbB1) is expressed in 90% of HNSCC and associated with poor prognosis. Despite clinical benefit (CB) of EGFR-targeted treatments such as cetuximab treatment resistance will occur resulting in a need for novel targeted treatments to improve prognosis. Afatinib is an ErbB Family Blocker that irreversibly blocks signaling from all relevant ErbB Family dimers and may overcome limitations of current EGFR-targeted treatments in HNSCC. In a randomized, proof-of-concept, Phase II trial, afatinib demonstrated comparable anti-tumor activity to cetuximab in pts with R/M HNSCC progressing after platinum-based therapy (Seiwert TY, et al; THNO, November 2011; Abs 40). Methods: LUX-H&N 1 is a phase III, randomized, open-label trial (NCT01345682) evaluating efficacy and safety of afatinib vs. MTX in pts with R/M HNSCC who have progressed after platinum-based therapy. Key eligibility criteria: confirmed R/M HNSCC not amenable to salvage surgery/radiotherapy; documented PD after cisplatin and/or carboplatin for R/M disease; any other than 1 previous platinum-based regimen for R/M disease; ECOG status 0 or 1; no PD ≤3 months of completion of curatively intended treatment for locoregionally advanced or metastatic HNSCC; and no prior EGFR-targeted small molecules treatment. Eligible pts are stratified into four strata: ECOG performance score (0 vs. 1) and prior use of EGFR-targeted antibody therapy (Yes/No) given in the R/M setting. Pts are randomized 2:1 to: afatinib (40mg/d orally) or MTX (40mg/m2 IV weekly). Dose changes are permitted according to absence/presence of drug-related AEs (afatinib: escalation to 50mg/d and/or reduction to 40, 30 then 20mg/d; MTX: escalation to 50mg/m2 and/or reduction to 40, 30 then 20mg/m2). Pts receive continuous treatment until PD or AEs requiring withdrawal. Randomized treatment may continue beyond PD in case of CB as judged by the investigator. The primary endpoint is PFS and secondary endpoints include OS, OR, health-related QOL and safety. Target enrolment is 474 pts and completion of pt recruitment and data analyses are awaited.
APA, Harvard, Vancouver, ISO, and other styles
12

Cupissol, Didier, Tanguy Y. Seiwert, Jérôme Fayette, Eva Ehrnrooth, Alice Sarah Blackman, Xiuyu Julie Cong, and Ezra E. W. Cohen. "A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 6001. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6001.

Full text
Abstract:
6001 Background: This open-label trial assessed the efficacy of the irreversible ErbB Family Blocker afatinib (A) vs cetuximab (C) in R/M HNSCC pts following failure of platinum-containing therapy. In Stage 1 (S1), A and C had confirmed objective response rates (RECIST 1.0) of 16.1% vs 6.5% by investigator review (8.1% vs 9.7% independent central review [ICR]; Seiwert TY, et al. MHNCS 2012. Abs 235). S2 data after crossover are presented. Methods: In S1, pts were randomized 1:1 to oral A 50 mg/day or IV C 250 mg/m2/wk (400 mg/m2 IV loading dose) until progressive disease (PD) or intolerable drug-related adverse events (DRAEs). Pts could then crossover to the other treatment arm (S2), with treatment given until further PD or intolerable DRAEs. Tumor response in S2 (RECIST 1.0) was evaluated at 4 wks after crossover and every 8 wks thereafter. Results: 56% of pts crossed over into S2: 32 from A to C and 36 from C to A. Of these, 88% crossed over after PD and 12% after intolerable DRAEs. Baseline characteristics of S2 pts were similar in the A and C groups and treatment duration in S1 prior to crossover was comparable (A: 3.7 [0.2–15.7] months; C: 3.5 [0.0–12.5] months). Median treatment duration in S2 was 2.1 (0.0–7.6) months for A and 1.2 (0.0–9.9) months for C. Tumor size decreases of ≥30% were observed in 1 pt in each treatment group (ICR). The disease control rate (DCR) for A was 33% vs 19% for C and the median progression-free survival time was 9.3 wks for A and 5.7 wks for C (ICR). The most frequently reported DRAEs (≥20%) for A were rash/acne (56%), diarrhea (53%) and stomatitis (22%), and for C was rash/acne (44%). DRAEs of ≥Grade 3 were seen in 47% of pts treated with A and 16% of pts treated with C. 12 A-treated patients had dose reductions to 40 mg and 1 pt had a further dose reduction to 30 mg; no C-treated pts had dose reductions. Conclusions: R/M HNSCC pts seem to benefit from sequential therapy with A/C or C/A, especially when using A treatment after C failure. Cross resistance is not universally present and further investigation of sequential treatment is warranted. Clinical trial information: NCT00514943.
APA, Harvard, Vancouver, ISO, and other styles
13

Maes, Eric. "Edith Franke, Christoph Kleine und Heinz Mürmel, Hg.: Devianz und Dynamik. Festschrift für Hubert Seiwert zum 65. Geburtstag. Critical Studies in Religion/ Religionswissenschaft (CSRRW), Band 8 (Göttingen: Vandenhoeck & Ruprecht, 2014), 263 S., ISBN 978-3-525-54037-4, € 100,00." Zeitschrift für Religionswissenschaft 27, no. 2 (September 9, 2019): 321–23. http://dx.doi.org/10.1515/zfr-2019-0028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Song, Alexander, Ron Ng, John Heller, Robin Petro, Ralph D’Agostino, Thomas Lycan, and Mercedes Porosnicu. "251 Factors evaluated as predictors of exceptional response to PD-1 inhibitors in patients with head and neck squamous cell cancer." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A272. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0251.

Full text
Abstract:
BackgroundImmunotherapy has recently emerged as an alternative to traditional chemotherapy in the management of recurrent or metastatic head and neck squamous cell cancer (HNSCC). PD-1 inhibitors were approved for HNSCC in 2016 with ORR of 13–18% and CR of 4%.1, 2 Current research focuses on identifying predictors of response for better patient selection. We present HNSCC patients with exceptional response to PD-1 inhibitors in an attempt to highlight biomarkers that correlated with their remarkable response.MethodsWe analyzed all cases of HNSCC treated with single agent PD-1 inhibitors in the last 4 years at Wake Forest Comprehensive Cancer Center. To identify exceptional responders, we followed the NIH Initiative definition: complete response to drug(s), where complete response is seen in less than 10% of patients receiving similar treatment or partial response lasting at least 6 months, where such response is seen in less than 10% of patients receiving similar treatment. We aimed to test all patients for PD-L1 expression, tumor genomics by Foundation Medicine platform and mutated circulating tumor DNA via Guardant 360 platform.ResultsBased on the above criteria, 11 patients were identified as exceptional responders, 9 of whom had metastatic spread to lung, liver or bones. 7 patients were treated for more than one year, and all achieved CR. 3 patients were treated for less than one year, and all achieved major PR with possible CR to be confirmed with next scans. One patient with metastatic HNSCC achieved CR after just 3 administrations of PD-1 inhibitor and has been in CR for 3.5 years. 9 patients were tested for PD-L1 before starting immunotherapy, and all presented levels above 5% by TPS and above 10% by CPS. Interestingly, three patients older than 75 had the highest PD-L1: 75% by TPS and 100% by CPS in two patients. TMB was found moderate or high in all 8 patients tested before starting immunotherapy. TP53 was found mutated both in tumor and in blood in all but 2 of the 10 tested patients, one of whom is the only HPV positive patient in our series. MSI was stable in all patients.ConclusionsThere are limited reports in the literature of exceptional responders to immunotherapy, particularly among HNSCC patients. High PD-L1 expression, moderate or high TMB and presence of mutated TP53 in both tumor and blood were present in almost all patients, recommending for further investigations as possible predictors of exceptional response to PD-1 inhibitors.Ethics ApprovalThe study was approved by Wake Forest University Institution’s Ethics Board, approval number IRB00056249.ReferencesT.Y. Seiwert, B. Burtness, R. Mehra, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17(7):pp. 956–965.Ferris RL, Blumenschein GJr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–67. 10.1056/NEJMoa1602252
APA, Harvard, Vancouver, ISO, and other styles
15

Bauman, Julie, Howard Burris, Jeffrey Clarke, Manish Patel, Daniel Cho, Martin Gutierrez, Ricklie Julian, et al. "798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A846. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0798.

Full text
Abstract:
BackgroundT-cell targeting of mutation-derived epitopes (neoantigens) has shown to drive anti-tumor responses. Immunizing patients against such neoantigens in combination with a checkpoint inhibitor (CPI) may elicit greater anti-tumor responses than CPI alone. Mutations are rarely shared between patients, thus requiring a personalized approach to vaccine design. mRNA-4157 is a lipid encapsulated mRNA based personalized cancer vaccine encoding neoantigens selected using a proprietary algorithm to induce neoantigen specific T cells and associated anti-tumor responses. This report includes updates from the mRNA-4157 Phase1(P1) study. The initial data was presented at ASCO2019.1MethodsThis study evaluates the safety and efficacy of mRNA-4157 as monotherapy in patients with resected solid tumors (Part A) and in combination with pembrolizumab in patients with advanced/metastatic solid tumors (Parts B). The selected solid tumors in Part A-B includes melanoma, bladder carcinoma, HPV-negative (HPV-neg) HNSCC, NSCLC, SCLC, MSI-High (MSI-h), or TMB-High cancers. Expansion cohorts includes patients with CPI-naïve MSS-CRC and HPV-neg HNSCC (Part C) and with resected melanoma (Part D). Patients receive up to 9 cycles (Q3W) of mRNA-4157 by intramuscular injection at up to 1 mg alone (Part A) or in combination with pembrolizumab (200 mg IV Q3W, Parts B-D). Pembrolizumab is administered for two cycles before the first dose of mRNA-4157 and may continue after 9 cycles of combination. Endpoints include safety, tolerability, efficacy and biomarker assessments.Results79 patients received mRNA-4157; 16 as monotherapy and 63 in combination with pembrolizumab. Only low grade and reversible treatment related AEs were reported. 14/16 Part A patients (3 melanoma, 11 NSCLC, 2 MSI-h CRC) remained disease free on study. 28 patients in Parts B (6 bladder, 2 HNSCC, 3 melanoma, 10 NSCLC, 2 SCLC, 4 MSI-h tumor, 1 TMB-h tumor), 27 patients in Part C (10 HNSCC and 17 MSS-CRC), and 8 patients with resected melanoma (Part D) received combination. 3 CR (1 HNSCC, 1 MSI-h CRC and 1 MSI-h prostate), and 8 PR (1 bladder, 4 HNSCC, 2 SCLC and 1 MSI-h endometrial) were observed with combination. Of 10 CPI-naïve HPV-neg HNSCC patients, the response rate was 50% (1CR, 4PR, 4SD) mPFS 9.8months, which compared favorably to published rates of ~14.6% mPFS 2.0months for pembrolizumab monotherapy.2 3 Biomarker assessments including immune gene expression profiling will be presented.Conclusions mRNA-4157 has an acceptable safety profile along with observed clinical responses in combination with pembrolizumab. Preliminary efficacy analysis from CPI-naïve relapsed/refractory HPV-neg HNSCC cohort suggests activity of this combination. Study is ongoing.Trial RegistrationNCT03313778Ethics ApprovalThe study was approved by each participating sites’ local IRB.ReferencesBurris H, et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. Journal of Clinical Oncology20 May 2019;37(15):2523-2523.Seiwert T, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17:956–65.Cohen E, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:10167:156-16.
APA, Harvard, Vancouver, ISO, and other styles
16

Gardiner, Mark Q., and Steven Engler. "Allies in the Fullness of Theory." Zeitschrift für Religionswissenschaft, September 13, 2021. http://dx.doi.org/10.1515/zfr-2021-0015.

Full text
Abstract:
Abstract In a recent article, Hubert Seiwert (2020) presents an approach to the study of religion that we develop (Engler and Gardiner, 2010) as an example of “empty theory”, and recommends how it can be salvaged. We clarify three things about our position: Seiwert misunderstands it at crucial points; it already includes his recommended rehabilitation; and it avoids postulating problematic and contentious ontological items, a potential problem that Seiwert’s own position has not addressed sufficiently.
APA, Harvard, Vancouver, ISO, and other styles
17

Schmidt-Leukel, Perry. "Religion: Historical Fact or Interpretive Theory? A Response to Hubert Seiwert." Zeitschrift für Religionswissenschaft, September 13, 2021. http://dx.doi.org/10.1515/zfr-2021-0012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Jahn, Sarah J. "Nun sag, wie hältst du’s mit der ‚Öffentlichkeit‘?" Zeitschrift für Religionswissenschaft 25, no. 1 (January 1, 2017). http://dx.doi.org/10.1515/zfr-2016-0029.

Full text
Abstract:
ZusammenfassungDer Beitrag befasst sich mit Überlegungen zur Positionsbestimmung von Religionswissenschaft in der Öffentlichkeit. Ausgehend von Rudolphs Auseinandersetzung über die ideologiekritische Funktion von Religionswissenschaft (1978) wird anhand der Positionen von Tworuschka (2008, 2015), McCutcheon (2001), Wilke (2005), Seiwert (1998) und Klinkhammer (2001) deutlich, dass die aktuelle Gretchenfrage nicht neu ist, es im Gegenteil schon konkrete, aber auch divergente Aussagen über die Rolle von Religionswissenschaft in der Öffentlichkeit gibt. Dem Verständnis einer historisch-kritisch arbeitenden und sich methodologisch-agnostisch verstehenden Religionswissenschaft folgend, wird ein Vorschlag unterbreitet, der den einseitigen Prozess der Wissensvermittlung hin zu einem wechselseitigen auflöst.
APA, Harvard, Vancouver, ISO, and other styles
19

"Wenn Du es eilig hast, gehe langsam. Das neue Zeitmanagement in einer beschleunigten Zeit (L. J. Seiwert)." Beton- und Stahlbetonbau 94, no. 5 (May 1999): 236. http://dx.doi.org/10.1002/best.199900830.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

"Erratum for the Research Article “Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy” by R. Cristescu, R. Mogg, M. Ayers, A. Albright, E. Murphy, J. Yearley, X. Sher, X. Q. Liu, H. Lu, M. Nebozhyn, C. Zhang, J. K. Lunceford, A. Joe, J. Cheng, A. L. Webber, N. Ibrahim, E. R. Plimack, P. A. Ott, T. Y. Seiwert, A. Ribas, T. K. McClanahan, J. E. Tomassini, A. Loboda, D. Kaufman." Science 363, no. 6430 (February 28, 2019): eaax1384. http://dx.doi.org/10.1126/science.aax1384.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography